Efficacy Study of Zeller Entspannung Film Coated Tablets on Acute Stress

NCT ID: NCT02189239

Last Updated: 2015-06-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2015-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the STRESS trial is to investigate in a mode of action setting the effect of Zeller Entspannung film coated tablets on saliva cortisol response versus Placebo after acute stress in healthy male volunteers. In addition, data on safety and tolerability of Zeller Entspannung will be obtained.

A third arm including no treatment is tested as well. Approximately 72 healthy volunteers will be included into this randomized, double blind study. Study duration will be 7 days, study medication intake will be over 4 days: participants will take the medication one tablet three times a day (morning, midday, evening) the first 3 days, whereas on day 4 only two tablets will be taken (morning and midday).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

The Primary Condition Studied for This Trial is Acute Stress

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Zeller Entspannung film coated tablets

Relaxing film coated tablets, 570 mg (Zeller Entspannung Filmtabletten), 3x1 tablet per day for the first three days (morning, midday, evening), at day four 2x1 tablet (morning, midday) preferably during meals with a glass of water.

Group Type ACTIVE_COMPARATOR

Zeller Entspannung film coated tablet

Intervention Type DRUG

Placebo tablets

Placebo medication is identical in presentation, color and shape, 3x1 tablet per day for the first three days (morning, midday, evening), at day four 2x1 tablet (morning, midday) during meals with a glass of water.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

No Treatment

No medication intake.

Group Type SHAM_COMPARATOR

No Treatment

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zeller Entspannung film coated tablet

Intervention Type DRUG

Placebo

Intervention Type DRUG

No Treatment

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age:18 - 45 years
* Written informed consent
* Male gender

Exclusion Criteria

* Any acute or chronic somatic or psychiatric disorder
* Smoking
* Any clinically relevant hepatic disorder
* Any clinically relevant renal disorder
* Any clinically relevant cardiac disorder
* Any clinically relevant respiratory disease (e.g. Asthma)
* Diabetes mellitus
* Known allergies to trial medication and excipients
* Alcohol or other drug abuse (e.g. cannabis)
* Concomitant participation in another clinical trial or \<4 weeks ago
* Participation in any psychotherapy
* Already participated in a TSST
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Max Zeller Soehne AG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Phase I Research Unit, University Hospital Basel

Basel, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Ze 185-4-2014-02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

GEL & MEDication Dysphagia
NCT07254663 RECRUITING
Clinical Study New Gel for Xerostomia
NCT04184908 UNKNOWN PHASE1